Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
A next-generation Novo Nordisk metabolic disorder drug led to statistically significant weight loss in a pivotal test in participants with obesity and type 2 diabetes, results it says support ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback